Nintedanibo tyrimų rezultatai įrodė veiksmingumą gydant plataus spektro fibrozuojančias intersticines plaučių ligas

Nintedanib is a tyrosine kinase inhibitor used to treat idiopathic pulmonary fibrosis. Its effectiveness has been proven in clinical trials. Still, there are more fibrosing interstitial lung diseases, but treatment options are limited. Because of the similarities in the pathophysiological processes of both idiopathic pulmonary fibrosis and a number of fibrosing interstitial lung diseases, preclinical and clinical studies have shown that nintedanib may be effective in a wide range of fibrosing interstitial lung diseases.